Altis Labs is accelerating clinical trials with AI endpoints.

Our multi-disciplinary team is on a mission to help reduce the time, cost, and failure rate plaguing therapeutic development so that patients can get access to novel, effective treatment sooner.

Trained on the industry's largest multimodal oncology database linked to survival outcomes, our AI model, IPRO, generates survival predictions from radiology scans to anticipate true clinical benefit beyond traditional imaging endpoints.

Leading global biopharmaceutical companies and cancer research centers analyze clinical trial data with IPRO to detect efficacy signals earlier and accelerate development decisions with confidence.

Altis is backed by OrbiMed, Qiming Venture Partners, Innovation Endeavors, Benchstrength, and other leading venture funds investing at the intersection of AI and drug development.